STOCK TITAN

Altimmune (NASDAQ: ALT) shareholders approve doubling share authorization

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Altimmune, Inc. reported results from its 2026 Annual Meeting and a key charter change. Stockholders approved an amendment to increase authorized common shares from 200,000,000 to 400,000,000, giving the company more capacity to issue stock in the future.

As of March 13, 2026, 130,105,177 shares were outstanding and entitled to vote, with 88,270,365 shares represented, a 67.8% quorum. Stockholders elected all director nominees, ratified Ernst & Young LLP as auditor, approved the advisory say-on-pay vote, expanded the 2019 Employee Stock Purchase Plan reserve from 403,500 to 1,108,827 shares, and authorized potential adjournment of the meeting to solicit additional proxies.

Positive

  • None.

Negative

  • None.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Authorized common shares 400,000,000 shares Increased from 200,000,000 via charter amendment
Shares outstanding and entitled to vote 130,105,177 shares As of March 13, 2026 record date
Shares represented at meeting 88,270,365 shares 67.8% of issued and outstanding entitled to vote
Auditor ratification votes for 84,959,584 shares Ernst & Young LLP ratified for year ending December 31, 2026
ESPP reserve increase From 403,500 to 1,108,827 shares 2019 Employee Stock Purchase Plan amendment approved
Amendment to increase authorized shares 63,684,172 for; 24,151,522 against; 434,671 abstain Proposal to raise authorized common shares to 400,000,000
Adjournment authorization 68,318,332 for; 18,755,920 against; 1,196,113 abstain Proposal to authorize adjournment to solicit additional proxies
Amended and Restated Certificate of Incorporation regulatory
"amended its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”)"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
quorum regulatory
"88,270,365 shares of common stock were present or represented by proxy ... representing a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes financial
"39,928,184 For ... 460,516 Abstain ... 35,855,584 Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
say-on-pay financial
"the “say-on-pay” proposal"
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
Employee Stock Purchase Plan financial
"amendment to the Company’s 2019 Employee Stock Purchase Plan (the “2019 ESPP”)"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
0001326190false--12-3100013261902026-04-162026-04-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 16, 2026

ALTIMMUNE, INC.

(Exact name of registrant as specified in its charter)

Delaware

 

001-32587

 

20-2726770

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

910 Clopper Road, Suite 201S

Gaithersburg, Maryland

20878

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number including area code: (240) 654-1450

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ALT

The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.03 Amendment to Article of Incorporation or Bylaws; Change in Fiscal Year.

On April 16, 2026, Altimmune, Inc. (the “Company”) amended its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) by filing a Certificate of Amendment with the Secretary of State of Delaware. The Certificate of Amendment reflected an amendment to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000 and was approved by the holders of more than a majority of the votes cast at the 2026 Annual Meeting of Shareholders as described in Item 5.07 below.

A copy of the Certificate of Amendment is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On April 16, 2026, Altimmune, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). As of March 13, 2026, the record date for the 2026 Annual Meeting, there were 130,105,177 shares of the Company’s common stock outstanding and entitled to vote at the 2026 Annual Meeting. A total of 88,270,365 shares of common stock were present or represented by proxy at the 2026 Annual Meeting, representing 67.8% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows:

Proposal No. 1: Election of Directors. The results were as follows:

  ​ ​ ​

Broker

Director

For

Withhold

Non-Votes

Jerome Durso, Chairman

47,577,875

 

4,836,906

 

35,855,584

John M. Gill

46,242,497

 

6,172,284

 

35,855,584

Philip L. Hodges

45,094,369

 

7,320,412

 

35,855,584

Diane Jorkasky, M.D.

45,332,124

 

7,082,657

 

35,855,584

Teri Lawver

44,926,060

 

7,488,721

 

35,855,584

Wayne Pisano

45,114,119

 

7,300,662

 

35,855,584

Mitchel Sayare, Ph.D.

45,194,158

 

7,220,623

 

35,855,584

Klaus O. Schafer, M.D., MPH

 

44,722,328

 

7,692,453

 

35,855,584

Catherine Sohn, Pharm D

 

45,298,692

 

7,116,089

 

35,855,584

Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results were as follows:

For

Against

Abstain

84,959,584

1,771,538

 

1,539,243

Proposal No. 3: Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal). The results were as follows:

For

Against

Abstain

Broker Non-Votes

39,928,184

12,026,081

460,516

 

35,855,584

Proposal No. 4: Vote to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended to increase the number of authorized shares of the Company’s common stock from 200,000,000 to 400,000,000. The results were as follows:

For

Against

Abstain

63,684,172

24,151,522

434,671

Proposal No. 5: Vote to approve an amendment to the Company’s 2019 Employee Stock Purchase Plan (the “2019 ESPP”) to increase the number of shares of the Company’s common stock reserved under the 2019 ESPP from 403,500 to 1,108,827. The results were as follows:

For

Against

Abstain

Broker Non-Votes

43,616,919

8,572,159

 

225,703

 

35,855,584

Proposal No. 6: Vote to authorize the adjournment of the 2026 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows:

For

Against

Abstain

68,318,332

18,755,920

 

1,196,113

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No.

  ​

Description

3.1

Certificate of Amendment to Amended and Restated Certificate of Incorporation regarding an increase in authorized shares

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALTIMMUNE, INC.

By:

 

/s/ Gregory Weaver

 

Name: Gregory Weaver

 

Title: Chief Financial Officer

Dated: April 16, 2026

FAQ

What corporate change did Altimmune (ALT) shareholders approve regarding authorized shares?

Shareholders approved doubling authorized common shares from 200,000,000 to 400,000,000. This change, adopted via a Certificate of Amendment, gives Altimmune greater flexibility to issue equity in the future for financing, acquisitions, or employee incentives.

How many Altimmune (ALT) shares were eligible to vote at the 2026 Annual Meeting?

A total of 130,105,177 Altimmune common shares were outstanding and entitled to vote as of March 13, 2026. At the meeting, 88,270,365 shares were present or represented by proxy, representing 67.8% of eligible shares and establishing a quorum.

Did Altimmune (ALT) shareholders approve the company’s auditor for 2026?

Yes, shareholders ratified Ernst & Young LLP as Altimmune’s independent registered public accounting firm for the year ending December 31, 2026. The vote was 84,959,584 shares for, 1,771,538 against, and 1,539,243 abstaining, indicating strong support.

How did Altimmune (ALT) shareholders vote on executive compensation (say-on-pay)?

Shareholders approved the advisory say-on-pay proposal on named executive officer compensation. The vote totaled 39,928,184 shares for, 12,026,081 against, 460,516 abstentions, and 35,855,584 broker non-votes, indicating a majority in favor of the disclosed pay programs.

What change was made to Altimmune’s (ALT) 2019 Employee Stock Purchase Plan?

Shareholders approved increasing the 2019 Employee Stock Purchase Plan share reserve from 403,500 to 1,108,827 common shares. This expansion allows more employee participation in share purchases under the plan over time, aligning staff incentives with company performance.

Were all Altimmune (ALT) director nominees elected at the 2026 Annual Meeting?

Yes, all director nominees, including Chairman Jerome Durso and eight other directors, were elected. For example, Durso received 47,577,875 votes for and 4,836,906 withheld, with 35,855,584 broker non-votes recorded on the director election proposals.

Did Altimmune (ALT) shareholders approve the ability to adjourn the 2026 meeting?

Shareholders authorized potential adjournment of the 2026 Annual Meeting to solicit additional proxies if needed. The adjournment proposal passed with 68,318,332 votes for, 18,755,920 against, and 1,196,113 abstaining, giving the board flexibility in managing the meeting process.

Filing Exhibits & Attachments

4 documents